THE NOVO NORDISK UK RESEARCH FOUNDATION
Latest income
£331k
Latest spending
£169k
Registered
1996
Accounts read
FY2025
Financial health, per its FY2025 accounts
The accounts state that unrestricted reserves increased to £183,676, which the trustees consider sufficient to cover a year's expenditure. However, the filing notes that funding has only been secured through 2026, with no confirmation for 2027 or subsequent years, leading to a cessation of new awards from 2027 onwards.
What the accounts disclose
Reserves policy: sufficient cash balance to cover expenditure for a year (held: £184k)
“It is the policy of the charity to maintain a sufficient cash balance to cover expenditure for a year.”
Per its FY2025 accounts as filed with the Charity Commission.
Going concern: noted by the trustees or auditor
“The trustees have not secured funding for 2027 or subsequent years and therefore will not be advertising awards for 2026 to ensure the Foundation has the funds to meet its existing award commitments.” — page 10
Per its FY2025 accounts as filed with the Charity Commission.
Related-party transaction: Donated services from Novo Nordisk Limited
“From 21 April 2025 the secretary took over the administration for the charity under a contract of employment with Novo Nordisk Limited. The associated costs have been recognised in the accounts as a donated service.” — page 4
“In 2025, £295,000 was received from the charity's sole donor, Novo Nordisk Limited” — page 4
Per its FY2025 accounts as filed with the Charity Commission.
Related-party transaction: Donations from Novo Nordisk Limited
“From 21 April 2025 the secretary took over the administration for the charity under a contract of employment with Novo Nordisk Limited. The associated costs have been recognised in the accounts as a donated service.” — page 4
“In 2025, £295,000 was received from the charity's sole donor, Novo Nordisk Limited” — page 4
Per its FY2025 accounts as filed with the Charity Commission.
Related-party transaction: Trustee travel expenses
“From 21 April 2025 the secretary took over the administration for the charity under a contract of employment with Novo Nordisk Limited. The associated costs have been recognised in the accounts as a donated service.” — page 4
“In 2025, £295,000 was received from the charity's sole donor, Novo Nordisk Limited” — page 4
Per its FY2025 accounts as filed with the Charity Commission.
Year-over-year changes
- Going concern: no going-concern doubt (FY2024) → going-concern doubt noted (FY2025).
Trustees
- Dr Danijela Tatovic
- Dr Dinesh Selvarajah
- Hannah Beba
- Nicholas Raymond Cahm
- Professor Pratik Choudhary
- Professor Richard Holt
- Professor Shareen Forbes
- Professor Steve Luzio
- Sandra Mulrennan
Income and spending
| Financial year end | Income | Spending |
|---|---|---|
| 31/12/2025 | £331k | £169k |
| 31/12/2024 | £387k | £285k |
| 31/12/2023 | £273k | £322k |
| 31/12/2022 | £272k | £327k |
| 31/12/2021 | £255k | £222k |
Common questions
Is THE NOVO NORDISK UK RESEARCH FOUNDATION financially healthy?
The accounts state that unrestricted reserves increased to £183,676, which the trustees consider sufficient to cover a year's expenditure. However, the filing notes that funding has only been secured through 2026, with no confirmation for 2027 or subsequent years, leading to a cessation of new awards from 2027 onwards. Its FY2025 accounts were independently examined.
Funders of similar charities
| Funder | Similar charities funded | Amount to them |
|---|---|---|
| SIR SAMUEL SCOTT OF YEWS TRUST | 3 | £35k |
| THE INMAN CHARITY | 3 | £17k |
| THE THOMPSON FAMILY CHARITABLE TRUST | 2 | £55k |
| CECIL PILKINGTON CHARITABLE TRUST | 2 | £8k |
| THE IAN ASKEW CHARITABLE TRUST | 2 | £3k |
| THE EARL FITZWILLIAM CHARITABLE TRUST | 2 | £2k |
| THE CHAMPNISS FOUNDATION | 1 | £221k |
| REUBEN FOUNDATION | 1 | £116k |